BSE filing, NSE: SRDAPRT. Summary written from the filing by ALFA Finder's alert engine.
Fresita Proteins Ltd: key numbers
- Share price
- ₹133.90
- Market cap
- ₹120.2 Cr
- Revenue (annual)
- ₹16.16 Cr
- Net profit (annual)
- ₹0.64 Cr
- P/E (TTM)
- 43.1×Sector 38.3×
- Promoter holding
- 80.47%-0.19% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fresita Proteins Ltd
All →Fresita Proteins Capital Structure Change
Fresita Proteins fixed a Rs. 89.76 Crore rights issue at Rs. 120 per share, record date October 30, 2026. Issue closes November 26, 2026.
- Value
- ₹89.76 Cr
Fresita Proteins Board Meeting Date
Fresita Proteins intimated a Rights Issue Committee meeting on October 26, 2026, to finalize its ₹90 Crore rights issue terms. No decisions have been made yet.
Fresita Proteins Annual General Meeting
Fresita Proteins Limited concluded its 35th Annual General Meeting on September 30, 2026. Shareholders transacted five resolutions, including approval for borrowing and investment limits of ₹1,000 Crore each.
Sarda Proteins Price Movement Clarification
Sarda Proteins Limited responded to a BSE query regarding recent stock price movement. The company stated the fluctuations are driven by market forces and conditions.
Sarda Proteins Other Announcement
Sarda Proteins Limited has changed its name to Fresita Proteins Limited, effective September 21, 2026. The name change received approval from the Ministry of Corporate Affairs and BSE.
Sarda Proteins Annual Report
Sarda Proteins Limited filed its 35th Annual Report for the financial year ended 31st March 2026 with the stock exchange.
Other board meeting date announcements
All →Pokarna Board Meeting Date
Pokarna Ltd intimated that its Board meets on 03 Nov 2026 to consider unaudited Q1 and H1 FY27 results. The trading window stays closed till 05 Nov 2026.
Mahaveer Infoway Board Meeting Date
Mahaveer Infoway Ltd scheduled a board meeting for 3 Nov 2026 to approve Q1 FY27 unaudited results and the limited review report. This is a routine prior intimation under Reg 29(1)(a).
Indowind Energy Board Meeting Date
Indowind Energy scheduled a board meeting on 5 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-approval.
Dhunseri Ventures Board Meeting Date
Dhunseri Ventures Ltd intimated that its Board will meet on 6 November 2026, inter alia to approve Q2 FY27 results. The trading window stays closed until 8 November 2026.
CESC Board Meeting Date
CESC Ltd scheduled its Board Meeting for 5 Nov 2026 to consider Q2/H1 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.
Genpharmasec Board Meeting Date
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.